Bibliografía del artículo
1. Girach A, Manner D, et al. Diabetic microvascular complications: can patientst risk be identified? A review. Int J Clin Pract 60(11):1471-83, 2010.
2. Villar E, Chang SH, et al. Incidences, treatments, outcomes, and sex effect on survival in patients with end-stage renal disease by diabetes status in Australia and New Zealand (1991-2005). Diabetes Care 30(12):3070-6, 2007.
3. Carranza K, Veron D, Cercado A, Bautista N, Pozo W, Tufro A, Veron D. Aspectos celulares y moleculares de la nefropatía diabética, rol del VEGF-A. Nefrologia 35(2):131-138, 2015.
4. Sochett EB, Cherney DZ, et al. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol 17(6):1703-9, 2006.
5. Pérez-García R, Martín-Malo A, Fort J, Cuevas X, Lladós F. Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER a multicentre, prospective, observational cohort study. Nephrol Dial Transplant 24:578-88, 2009.
6. Correa Rotter R. Nefropatía diabética. En: Treviño Becerra A. Tratado de nefrología. México, DF, El Prado, t 1: p. 663, 2003.
7. Pérez-García R, Martín-Malo A, Fort J, Cuevas X, Lladós F. Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER -a multicentre, prospective, observational cohort study. Nephrol Dial Transplant 24:570-75, 2009.
8. Carranza K, Verón D, Cercado A, Bautista N, Pozo W, Trufo A, Verñon D. Aspectos celulares y moleculares de la nefropatía diabética, rol del VEGF-A. Nefrología 35(2):131-138, 2015.
9. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world. A growing challenge. N Engl J Med 356:213-5, 2007.
10. Tong Z, Yang Z, Patel S Et Al. Promoter polymorphism of the erytropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA 105:6998-7003, 2008.
11. Sociedad Chilena de Nefrología. Registro de diálisis. XXV. Cuenta de Hemodiálisis Crónica en Chile, Agosto 2005.
12. Rodríguez Constantín A, Rodríguez Beyrís RP. Insuficiencia renal crónica en pacientes con diabetes mellitus de tipo 2 en un área de salud [artículo en línea]. Medisan 13(6), 2009.
13. Gu D, Reynolds K, Duan X, Xin X, Chen J, Wu X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia 46(9):1190-8, 2008 [citado 15 Jun 2009].
14. Domínguez E, Seuc A, Aldana D, Licea M, Díaz O, López L. Impacto de la diabetes sobre la duración y calidad de vida de la población cubana: años 1990, 1995, 2000 y 2003. Rev Cubana Endocrinol [serie en Internet] 17(2), 2006 [citado 17 Jun 2009].
15. WHO. World health report 2003. Chapter 6: Neglected global epidemics: three growing threats. Ginebra, Suiza, 2003.
16. Seuc A, Domínguez E, Díaz O. Esperanza de vida ajustada por diabetes. Rev Cubana Endocrinol 14:32-6, 2003.
17. Díaz Díaz O. Importancia de los estudios de mortalidad en diabéticos. Rev Cubana Endocrinol 12:137-8, 2001.
18. WHO. World health report 2003. Chapter 6: Neglected global epidemics: three growing threats. Ginebra, Suiza, 2003.
19. Brenner BM, Cooper ME, De Zeew D et al, for the RENAAL Study Group. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861-869, 2011.
20. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2010.
21. Wantier JL, Guillausseau RJ. Advanced glycation end products, their receptors and diabeticangiopathy.Diabetes Metab 29:86-7, 2008.
22. Kalousova M, Zima T, Tesar V, Dusilova-Sulkova S, Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res 579:37-46, 2009.
23. Setter SM. Biochemical pathways for microvascular complications of diabetes mellitus. Ann Pharmacother 37:1858-66, 2010.
24. Zerbini G, Bonfanti R, et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes 55(9):2620-5, 2007.
25. Ewens KG, George RA, et al. Assessment of 115 candidate genes for diabetic nephropathy by transmission/ disequilibrium test. Diabetes 54(11):3305-18, 2005.
26. Gerth J, Cohen CD, et al. Collagen type VIII expression in human diabetic nephropathy. Eur J Clin Invest 37(10):767-73, 2007.
27. Ichinose K, Kawasaki E, et al. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol 27(6):554-64, 2007.
28. Remón C, Quirós PL, Portolés R. Consecuencias. y factores relacionados con la remisión tardía en la enfermedad renal crónica. Nefrología 29(S5):57-61, 2009.
29. Tzamaloukas AH, Friedman EA. Manual de diálisis. In: Daugirdas JT, Blake PG, eds. Diabetes, 2nd ed. Barcelona, Masson, pp. 472-485, 2003.
30. Hemodialysis Adequacy 2006 Work Group. Clinical Practice Guidelines for Hemodialysis Adequacy. Am J Kidney Dis 48:3-90, 2006.
31. Tzamaloukas AH, Friedman EA. Manual de diálisis. In: Daugirdas JT, Blake PG, eds. Diabetes, 2nd ed. Barcelona,Masson, pp. 472-485, 2013.
32. Lassalle M, Labeeuw M, Frimat L, Villar E, Joyeux V, Couchoud C, et al. Age and comorbidity may explain the paradoxical association of an early dialysis start with poor survival. Kidney Int 77:700-7, 2010.
33. Martínez-Castelao A, Górriz JL, García-López F. Perceived health-related quality of life and comorbidity in diabetic patients starting dialysis (CALVIDIA study). J Nephrol 17:1-8, 2014.
34. Depner TA. Refinements and application of urea modeling. In: Depner TA, ed. Prescribing hemodialysis: a guide to urea modelling. Boston, Kluwer, pp. 167-94, 2011.
35. Konner K. Primary vascular access in diabetic patients: an audit. Nephrol Dial Transplant 15:1317-25, 2010.
36. Díaz-López M, Plaza-Martínez A, Riera-Vázquez R, Juliá-Montoya J, Manuel-Rimbau E, Corominas-Roura C, et al. Utilidad de las fístulas arteriovenosas autólogas para hemodiálisis en pacientes diabéticos. Angiología 54:301-7, 2002.
37. Leehey DJ. Hemodialysis in the diabetic patient with end-stage renal disease. Renal Fail 16:547-53, 2014.
38. Standards of Medical Care in Diabetes 2010. Diabetes Care 33:4-10, 2010.
39. Drechsler C, Krane V, Ritz E, März W, Wanner C. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 120:2421-8, 2009.
40. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 50:865-79, 2007.
41. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 39:297-307, 2012.
42. Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out diabetes in ESRD. Semin Dialysis 23:148-56, 2010.
43. Lou LM, Gota R, Álvarez R, Gutiérrez Colon JA. Parámetros nutricionales de los pacientes en diabéticos en hemodiálisis. Nefrología 15:385-6, 2010.
44. Watanabe Y, Yuzawa Y, Mizumoto D, Tamai H, Itoh Y, Kumon S, et al. Long-term followup study of 268 diabetic patients undergoing haemodialysis, with special attention to visual acuity and heterogeneity. Nephrol Dial Transplant 8:725-34, 2013.
45. Jaar BG, Astor BC, Berns JS, Powe NL. Predictors of amputation and survival following lower extremity revascularization in hemodialysis patients. Kidney Int 65:613-20, 2004.
46. Combe C, Albert JM, Bragg-Gresham JL, Andreucci VE, Disney A, Fukuhara S, et al. The burden of amputation among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 54:680-92, 2009.
47. Bernal Pedreño E, Salces Sáez E, Sambruno Giráldez A. Exploración del pie a los pacientes diabéticos en una unidad de hemodiálisis. Rev Soc Esp Enferm Nefrol 12:111-6, 2009.
48. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 67:1684-91, 2010.
49. US Renal Data System. USRDS 2008 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008 (www.usrds.org).
50. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 30:383-93, 2013.
51. Levin A. Consequences of late referral on patient's outcomes. Nephrol Dial Transplant 15(Suppl 3):8-13, 2010.
52. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16:489-95, 2005.
53. Meyer KB, Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the National Kidney Foundation Task Force on Cardiovascular Disease. J Am Soc Nephrol 9(Suppl):S31-42, 2008.
54. Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profi les and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 80(10):1270-7, 2005.
55. US Renal Data System. USRDS 2006 Annual Data Report. Atlas of end stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006. Am J Kidney Dis 47(Suppl 1):S1, 2006.
56. Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 15(Suppl 1):S25-9, 2014.
57. Kimmel Pl, Varela MP, Rolf A, Peterson Rl, Weihs KL, Simmens SJ, et al. Interdialytic weight gain and survival in hemodialysis patients: effects of duration of ESRD and diabetes mellitus. Kidney Int 57:1141-51, 2010.
58. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ. HMGCoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297-304, 2012.
59. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, et al. HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45:119-26, 2010.
60. Wanner C, Krane V, März W, for the German Diabetes and Dialysis Study Group. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-48, 2010.
61. Jaar BG, Coresh J, Plantinga LC. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 143:174, 2010.
62. Sutherland DER, Gruessner RWG, Dunn DL, Matas AJ, Humar A, Kandaswamy R, et al. Lessons learned from more than 1000 pancreas transplants at a single institution. Ann Surg 233:463-501, 2011.
63. Odorico JS, Sollinger HW. Technical and Immunosuppressive advances in transplantation for insulin-dependent diabetes mellitus. World J Surg 26:194-211, 2012.
64. American Diabetes Association. Pancreas transplantation in type 1 diabetes. Diabetes Care 27(Suppl 1):105, 2014.
65. Fernández-Balcells M, Esmatjes E, Ricart MJ, Casmitjamna R, Astudillo E. Fernández-Cruz L. Successful pancreas and kidney transplantation: a view of metabolic control. Clin Transplant 12:582-7, 2008.